Two Phase 3 Trials of Baricitinib for Alopecia Areata
In this medfyle
Phase 3 data from the BRAVE-AA trials show baricitinib delivers superior hair regrowth to placebo.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It is a summary of an article originally published in the New England Journal of Medicine.
The summary was prepared by Marie Farrow on behalf of Medfyle and reviewed by Bianca Maria Piraccini, MD, PhD.
Original article:
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.
The authors of the original article, and the publisher, were not involved in the creation of the summary.
